| 摘要 |
Use of effective amounts of gamma-linolenic acid (GLA) or dihomogammalinolenic acid (DGLA) in the preparation of a medicament for the treatment of Huntington's Chorea in both people who are genetically predisposed to the disease and those who are not. The GLA or DGLA can be administered with arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapentaenoic (EPA), stearidonic acid or n-6 or n-3 essential fatty acids.
|
